Search results for " Drug"

showing 10 items of 3138 documents

Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.

2016

Drug attrition rates due to hepatotoxicity are an important safety issue considered in drug development. The HepG2 hepatoma cell line is currently being used for drug-induced hepatotoxicity evaluations, but its expression of drug-metabolizing enzymes is poor compared with hepatocytes. Different approaches have been proposed to upgrade HepG2 cells for more reliable drug-induced liver injury predictions. Areas covered: We describe the advantages and limitations of HepG2 cells transduced with adenoviral vectors that encode drug-metabolizing enzymes for safety risk assessments of bioactivable compounds. Adenoviral transduction facilitates efficient and controlled delivery of multiple drug-metab…

0301 basic medicineDrugmedia_common.quotation_subjectGenetic VectorsBiologyPharmacologyToxicologyENCODERisk AssessmentAdenoviridae03 medical and health sciencesToxicity TestsmedicineAnimalsHumansmedia_commonPharmacologyLiver injurychemistry.chemical_classificationReproducibility of ResultsGeneral MedicineHep G2 Cellsmedicine.disease030104 developmental biologyEnzymemedicine.anatomical_structureDrug developmentchemistryPharmaceutical PreparationsHepg2 cellsHepatocyteDrug DesignCancer researchHepatocytesChemical and Drug Induced Liver InjuryDrug metabolismExpert opinion on drug metabolismtoxicology
researchProduct

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems

2018

Despite growing research, drug-induced liver injury (DILI) remains a serious issue of increasing importance to the medical community that challenges health systems, pharmaceutical industries and drug regulatory agencies. Drug-induced cholestasis (DIC) represents a frequent manifestation of DILI in humans, which is characterised by an impaired canalicular bile flow resulting in a detrimental accumulation of bile constituents in blood and tissues. From a clinical point of view, cholestatic DILI generates a wide spectrum of presentations and can be a diagnostic challenge. The drug classes mostly associated with DIC are anti-infectious, anti-diabetic, anti-inflammatory, psychotropic and cardiov…

0301 basic medicineDrugmedicine.drug_classmedia_common.quotation_subjectReceptors Cytoplasmic and NuclearMiscellaneous DrugsIn Vitro TechniquesToxicologyBioinformaticsBile flow03 medical and health sciences0302 clinical medicineCholestasismedicineAnimalsBileHumansDrug induced cholestasismedia_commonCholestasisPolymorphism GeneticBile acidbusiness.industryMembrane Transport ProteinsGeneral Medicinemedicine.diseaseGastrointestinal MicrobiomeMicroRNAs030104 developmental biologyCardiovascular agent030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFood ScienceHealthcare systemFood and Chemical Toxicology
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

Nano-engineered skin mesenchymal stem cells: potential vehicles for tumour-targeted quantum-dot delivery

2017

Nanotechnology-based drug design offers new possibilities for the use of nanoparticles in imaging and targeted therapy of tumours. Due to their tumour-homing ability, nano-engineered mesenchymal stem cells (MSCs) could be utilized as vectors to deliver diagnostic and therapeutic nanoparticles into a tumour. In the present study, uptake and functional effects of carboxyl-coated quantum dots QD655 were studied in human skin MSCs. The effect of QD on MSCs was examined using a cell viability assay, Ki67 expression analysis, and tri-lineage differentiation assay. The optimal conditions for QD uptake in MSCs were determined using flow cytometry. The QD uptake route in MSCs was examined via fluore…

0301 basic medicineEndosomeGeneral Physics and Astronomyquantum dots02 engineering and technologylcsh:Chemical technologyEndocytosislcsh:TechnologyFull Research PaperFlow cytometry03 medical and health sciencesmedicineNanotechnologyendocytosislcsh:TP1-1185General Materials ScienceCD90stem cell differentiationViability assayMicropinocytosisElectrical and Electronic Engineeringlcsh:Sciencemesenchymal stem cellsmedicine.diagnostic_testlcsh:TChemistryMesenchymal stem cell021001 nanoscience & nanotechnologylcsh:QC1-999Cell biologyNanoscience030104 developmental biologyTargeted drug deliverylcsh:Q0210 nano-technologylcsh:PhysicsBeilstein Journal of Nanotechnology
researchProduct

Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells

2016

Anabolic androgenic steroids (AAS) are among the drugs most used by athletes for improving physical performance, as well as for aesthetic purposes. A number of papers have showed the side effects of AAS in different organs and tissues. For example, AAS are known to suppress gonadotropin‐releasing hormone, luteinizing hormone, and follicle‐stimulating hormone. This study investigates the effects of nandrolone on testosterone biosynthesis in Leydig cells using various methods, including mass spectrometry, western blotting, confocal microscopy and quantitative real‐time PCR. The results obtained show that testosterone levels increase at a 3.9 μM concentration of nandrolone and return to the ba…

0301 basic medicineEnzymologicMalePhysiologyClinical BiochemistryAndrogenAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Physiology; Clinical Biochemistry; Cell BiologyAnabolic AgentsOriginal Research ArticlesNandroloneTestosteroneOriginal Research ArticleTestosteroneAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; Testosterone; Clinical Biochemistry; Cell Biology; Physiology; Medicine (all)Steroidogenic acute regulatory proteinMedicine (all)Leydig CellsSteroid 17-alpha-HydroxylaseCYP17A1PhosphoproteinAndrogensDrugLuteinizing hormonemedicine.drugAnabolic Agents; Androgens; Animals; Cell Line; Cell Survival; Dose-Response Relationship Drug; Gene Expression Regulation Enzymologic; Leydig Cells; Male; Nandrolone; Phosphoproteins; Rats; Steroid 17-alpha-Hydroxylase; TestosteroneLeydig Cellendocrine systemmedicine.medical_specialtyCell SurvivalBiologyGene Expression Regulation EnzymologicCell LineDose-Response Relationship03 medical and health sciencesDownregulation and upregulationIn vivoInternal medicinemedicineAnimalsDose-Response Relationship DrugAnimalCell BiologyPhosphoproteinsRats030104 developmental biologyEndocrinologyGene Expression RegulationNandroloneAnabolic AgentRatHormone
researchProduct

Biosynthesis of heme O in intraerythrocytic stages of Plasmodium falciparum and potential inhibitors of this pathway

2019

A number of antimalarial drugs interfere with the electron transport chain and heme-related reactions; however, the biosynthesis of heme derivatives in Plasmodium parasites has not been fully elucidated. Here, we characterized the steps that lead to the farnesylation of heme. After the identification of a gene encoding heme O synthase, we identified heme O synthesis in blood stage parasites through the incorporation of radioactive precursors. The presence of heme O synthesis in intraerythrocytic stages of Plasmodium falciparum was confirmed by mass spectrometry. Inabenfide and uniconazole–P appeared to interfere in heme synthesis, accordingly, parasite growth was also affected by the additi…

0301 basic medicineErythrocytesANIMAIS PARASITOS030231 tropical medicinePlasmodium falciparumProtozoan Proteinslcsh:MedicineHemePlasmodiumArticle03 medical and health scienceschemistry.chemical_compoundAntimalarials0302 clinical medicinePrenylationBiosynthesisBiophysical chemistryParasite physiologyparasitic diseasesHumansHeme O synthesislcsh:ScienceHemeGeneMultidisciplinaryAlkyl and Aryl TransferasesbiologyInhibitorslcsh:RPlasmodium falciparumbiology.organism_classificationHeme OElectron transport chainPlasmodium Falciparum030104 developmental biologychemistryBiochemistrylcsh:QPlasmodium parasitesAntimalarial drugs
researchProduct

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

2017

Abstract: Introduction: The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. Areas Covered: This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies. Expert opinion: Most of the TKR share …

0301 basic medicineFibroblast Growth FactorDruggabilityFibroblast growth factorTyrosine-kinase inhibitorReceptor tyrosine kinase0302 clinical medicineNeoplasmsFGFR inhibitorsFGFMolecular Targeted TherapyCancerCancer; FGF; FGFR; FGFR inhibitors; Drug Resistance Neoplasm; Fibroblast Growth Factors; Gene Fusion; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Receptors Fibroblast Growth Factor; Signal Transduction; Hematology; Oncology; Geriatrics and GerontologybiologyFGFRHematologyFGFR inhibitorOncologyFibroblast growth factor receptor030220 oncology & carcinogenesisembryonic structuresSignal transductionbiological phenomena cell phenomena and immunityGene FusionHumanSignal Transductionmusculoskeletal diseasesanimal structuresmedicine.drug_classProtein Kinase Inhibitor03 medical and health sciencesmedicineHumansProtein Kinase InhibitorsCancer; FGF; FGFR; FGFR inhibitorsbusiness.industryCancermedicine.diseaseMolecular biologyReceptors Fibroblast Growth FactorFibroblast Growth Factors030104 developmental biologyDrug Resistance NeoplasmCancer cellMutationbiology.proteinNeoplasmHuman medicineGeriatrics and GerontologybusinessCritical reviews in oncology/hematology
researchProduct

Lawsone derivatives target the Wnt/β-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells.

2017

Abstract Multidrug resistance (MDR) represents a serious problem in cancer treatment. One strategy to overcome this obstacle is to identify agents that are selectively lethal to MDR cells. The aim of this study was to discover novel compounds against MDR leukemia and to determine the molecular mechanisms behind collateral sensitivity. A library of 1162 compounds was tested against parental, drug-sensitive CCRF-CEM cells using the resazurin assay. A total of 302 compounds showed reasonable activity (less than 50% cell viability). Eleven out of 30 lawsone derivatives revealed considerable collateral sensitivity in MDR P-glycoprotein (Pgp)-overexpressing CEM/ADR5000 cells. They reduced β-caten…

0301 basic medicineFrizzledAntineoplastic AgentsPharmacologyBiologyBiochemistryLawsone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineHumansViability assaybeta CateninPharmacologyDose-Response Relationship DrugMolecular StructureWnt signaling pathwayResazurinPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseMultiple drug resistanceWnt ProteinsLeukemia030104 developmental biologychemistryCell cultureDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchReactive Oxygen SpeciesNaphthoquinonesSignal TransductionBiochemical pharmacology
researchProduct